Equillium to Present New Data and Insights on the CD6-ALCAM Pathway in Lupus Nephritis at ACR 2019
November 06, 2019 08:05 ET
|
Equillium
LA JOLLA, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Aptinyx Announces Results of Phase 2 Fibromyalgia Study of NYX-2925 Have Been Selected for Late-Breaking Presentation at the American College of Rheumatology Annual Meeting
October 28, 2019 07:57 ET
|
Aptinyx Inc.
Study met primary and secondary endpoints – statistically significant effects on neuroimaging biomarkers and patient-reported measures ePoster to be presented at ACR Annual Meeting on Tuesday,...
Corbus Pharmaceuticals Completes Enrollment of RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
May 02, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Company anticipates topline results of RESOLVE-1 study in the summer of 2020Systemic sclerosis (SSc) is a chronic, rare systemic autoimmune disease affecting approximately 200,000 people in the U.S.,...
Veritas Farms Harvests Exclusive Relationship with Bendcare's Oasis Health to Create Physician Formulated Sunrise and Eclipse Product Line Extension Distributed by AARA, the Largest Rheumatology Group in the U.S.
April 16, 2019 10:39 ET
|
Veritas Farms, Inc.
Fort Lauderdale, FL, April 16, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Veritas Farms, Inc. (OTCQB: VFRM), a vertically-integrated agribusiness focused on the production of full spectrum hemp...
Corbus Pharmaceuticals Provides Management Team Updates
March 28, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Mark Tepper, Ph.D., transitions to role of external Senior Scientific Advisor Robert Discordia, Ph.D., role expanded to lead Chemistry, Manufacturing and Controls operationsSergei Atamas, M.D.,...
Medexus présente une déclaration d’acquisition
January 07, 2019 14:35 ET
|
Medexus Pharmaceuticals Inc.
MONTRÉAL, 07 janv. 2019 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (anciennement Pediapharm Inc.) (la « Société ») (TSXV : MDP, OTCQB : PDDPF) a annoncé aujourd’hui la présentation d’une...
Medexus Files Business Acquisition Report
January 07, 2019 14:35 ET
|
Medexus Pharmaceuticals Inc.
MONTREAL, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.) (the “Company”) (TSXV: MDP, OTCQB: PDDPF) today announced the filing of the Business Acquisition...
Medexus Announces New Chief Executive Officer, Chair of the Board of Directors, Other Organizational Updates and Equity Incentive Grants
December 17, 2018 14:30 ET
|
Medexus Pharmaceuticals Inc.
MONTREAL, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.) (the “Company”) (TSXV: PDP, OTCQB: PDDPF) today announced organizational changes designed to...
Pediapharm Announces Name Change, Consolidation and Debenture Repayment
December 13, 2018 15:44 ET
|
Medexus Pharmaceuticals Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW. ...
Pediapharm annonce les résultats de son deuxième trimestre – BAIIA ajusté record, ventes records et un 13e trimestre consécutif de croissance d’un exercice à l’autre
November 27, 2018 08:00 ET
|
Pediapharm Inc.
CE COMMUNIQUÉ NE PEUT ÊTRE DISTRIBUÉ AUX AGENCES DE TRANSMISSION AMÉRICAINES NI DIFFUSÉ AUX ÉTATS-UNIS. NE PAS RESPECTER CETTE CONSIGNE PEUT CONSTITUER UNE VIOLATION DE LA LOI SUR LES TITRES DES...